-
Ultimovacs ASA: Mandatory notification of trade by primary insiders
-
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
-
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
-
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
-
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
-
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
-
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
